Inventiva Pharma
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $216.0Mattributed |
|---|---|
| Latest round | seed, $160.9M, 2025-11-15attributed |
| Founded | 2012 |
| Headquarters | Daix, France |
| Industry | bio |
| Stage | series-b+ |
| Website | inventivapharma.com |
Inventiva Pharma is a French clinical-stage biopharma focused on lanifibranor, an oral pan-PPAR agonist for metabolic dysfunction-associated steatohepatitis. It targets MASH patients with advanced fibrosis lacking oral options. The Phase 3 NATiV3 trial of 1,000+ patients is expected to read out in H2 2026.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-11-15 | seed | $160.9M | undisclosed |
Detected tech stack
Apache HTTP Server, Modernizr, Yoast SEO 27.5, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, particles.js, Polylang, DoubleClick Floodlight, CookieYes 3.4.2, OneSignal, OWL Carousel
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $160.9M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $216.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | inventivapharma.com, read 2026-05-02 |
| Description | self-reported | inventivapharma.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.